Role of drugs in prevention of coronary restenosis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1399, 2003-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era

By Rodriguez Alfredo E

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 4, 2009-12 ,pp. : 561-576

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological Approaches to the Prevention of Restenosis After Coronary Angioplasty

By Hamon M.

Drugs & Aging, Vol. 13, Iss. 4, 1998-10 ,pp. : 291-301

Adis International

Access to resources Recommend Favorite

Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries

By Gruberg L. Waksman R.

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 5, 2001-05 ,pp. : 891-907

Informa Healthcare

Access to resources Recommend Favorite

Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 15, 2012-08 ,pp. : 1613-1620

Bentham Science Publishers

Access to resources Recommend Favorite

Glucocorticoids in the Prevention of Restenosis After Coronary Angioplasty: Therapeutic Potential

By Ferrero Valeria Ribichini Flavio Pesarini Gabriele Brunelleschi Sandra Vassanelli Corrado

Drugs, Vol. 67, Iss. 9, 2007-01 ,pp. : 1243-1255

Adis International

Access to resources Recommend Favorite